Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Appointed director
CC transcript
Quarterly results
Credit agrmnt [a]
Director departure

Pediatrix Medical Group, Inc. (MD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Pediatrix Medical Group Reports Second Quarter Results FORT LAUDERDALE, Fla., August 3, 2023 - Pediatrix Medical Group, Inc. , the nation’s leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.34 per share for the three months ended June 30, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.39. For the 2023 second quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $501 million; • Income from continuing operations of $28 million; and • Adjusted EBITDA of $59 million. “Our second quarter operating results were in line with our expectations and reflect stable patient volumes and strong cash gene..."
06/16/2023 4 Swift James D (CEO) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Sold 13,193 shares @ $14.14, valued at $186.5k
06/08/2023 4 Pickert Curtis (EVP, COO) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Gifted 1,166 shares @ $0
06/02/2023 4 Pickert Curtis (EVP, COO) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Paid exercise price by delivering 376 shares @ $13.3, valued at $5k
06/02/2023 4 Wood Lee (EVP, Natl & Market Operations) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Paid exercise price by delivering 407 shares @ $13.3, valued at $5.4k
05/26/2023 4 ORDAN MARK S (Director) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Sold 33,000 shares @ $13.26, valued at $437.6k
05/24/2023 144 Form 144 - Report of proposed sale of securities:
05/19/2023 144 Form 144 - Report of proposed sale of securities:
05/18/2023 144 Form 144 - Report of proposed sale of securities:
05/15/2023 4 SANSONE GUY P (Director) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Granted 10,965 shares @ $0
05/15/2023 4 Weis Shirley A (Director) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Granted 10,965 shares @ $0
05/15/2023 4 Rucker Michael A. (Director) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Granted 10,965 shares @ $0
05/15/2023 4 Starcher John M. Jr. (Director) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Granted 10,965 shares @ $0
05/15/2023 4 McEachin Thomas (Director) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Granted 10,965 shares @ $0
05/15/2023 4 ORDAN MARK S (Director) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Granted 9,463 shares @ $0
05/15/2023 4 Linynsky Laura A (Director) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Granted 10,965 shares @ $0
05/11/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/10/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 SC 13G/A ALLIANCEBERNSTEIN L.P. reports a 10% stake in Pediatrix Medical Group Inc
05/04/2023 8-K Quarterly results
05/02/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/02/2023 8-K Quarterly results
Docs: "Pediatrix Medical Group Reports First Quarter Results FORT LAUDERDALE, Fla., May 2, 2023 - Pediatrix Medical Group, Inc. , the nation’s leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.17 per share for the three months ended March 31, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.23. For the 2023 first quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $491 million; • Income from continuing operations of $14 million; and • Adjusted EBITDA of $40 million. “Our first quarter operating results were in line with our expectations and reflected modest improvements in revenue cycle managemen..."
03/31/2023 ARS Form ARS - Annual Report to Security Holders:
03/31/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/31/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/22/2023 3 Wood Lee (EVP, Natl & Market Operations) has filed a Form 3 on Pediatrix Medical Group, Inc.
02/22/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
02/14/2023 SC 13G/A EARNEST PARTNERS LLC reports a 7.9% stake in Pediatrix Medical Group, Inc.
02/09/2023 SC 13G/A FMR LLC reports a 0% stake in PEDIATRIX MEDICAL GROUP INC
01/23/2023 SC 13G/A BlackRock Inc. reports a 16.5% stake in Pediatrix Medical Group, Inc.
01/20/2023 SC 13D/A Starboard Value LP reports a 4% stake in Pediatrix Medical Group, Inc.
01/04/2023 4 ORDAN MARK S (CEO) has filed a Form 4 on Pediatrix Medical Group, Inc.
Txns: Paid exercise price by delivering 98,932 shares @ $14.86, valued at $1.5M
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy